ML
CGTX icon

McAdam LLC’s Cognition Therapeutics CGTX Stock Holding History

McAdam LLC’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.1K Sell
69,953
-4,156
-6% -$4.84K ﹤0.01% 438
2025
Q4 		$100K Buy
74,109
+2,034
+3% +$3.3K ﹤0.01% 411
2025
Q3 		$97.3K Buy
+72,075
New +$98.3K ﹤0.01% 389

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

McAdam LLC's CGTX Position: Q1 2026 in Review

McAdam LLC reduced its Cognition Therapeutics (CGTX) stake by 5.6% in Q1 2026, selling an estimated $4.84K and leaving 69,953 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #438.

McAdam LLC first reported a position in CGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $100K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • McAdam LLC held 69,953 shares of Cognition Therapeutics worth $53.1K as of Q1 2026.
  • McAdam LLC sold 4,156 Cognition Therapeutics shares in Q1 2026, an estimated $4.84K.
  • Cognition Therapeutics made up ﹤0.01% of McAdam LLC's portfolio in Q1 2026, its #438 holding.
  • McAdam LLC first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • McAdam LLC's Cognition Therapeutics position peaked at $100K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on McAdam LLC's 13F filing for Q1 2026, filed 8 May 2026.